WCG released results from the 2023 CenterWatch Global Site Relationship Benchmark Survey Report. The results show how more than 3,600 representatives from clinical trial sites around the world rate their sponsor and clinical research organization (CRO) relationships as the industry is adjusting to a post-pandemic world.
New to the report this year is the ability for sponsors to evaluate how the CRO that acts on their behalf impacts their site ratings.
Site respondents were asked to rank the overall reputation of 77 sponsors and 34 CROs and rate the relative importance of performance related attributes. They were then requested to identify the organizations they had worked with most during the past two years and rate the performance of those organizations against the attributes.
Both sponsors and CROs received the highest performance scores for the quality of their communication with site staff and their responsiveness to site inquiries, as well as for being professional, organized, and knowledgeable. Areas of improvement based on site recommendations included feedback from sites and study participants/participant groups in protocol design and support for initiatives to help sites build stronger relationships with study volunteers. Recommendations for improvement for CROs included greater efficiency in contract and budget negotiation and receiving ongoing feedback from sites. Sites also recommended more flexibility among both sponsors and CROs to modify budgets.
WCG CenterWatch included many of the same performance attributes in its 2017, 2019, and 2021 surveys so that longitudinal comparisons can be made between those results, and trends evaluated. An in-depth general report, which includes the 2023 sponsor and CRO rankings, is available at https://www.centerwatch.com/products/category/1061-benchmark-reports.
WCG Unveils Results from 2023 Global Site Relationship Benchmark Survey Report. (2023 May, 24). Cision PR Newswire.
Zenocutuzumab Shows Durable Efficacy in NRG1 Fusion-Positive Cancers in Phase II eNRGy Trial
February 13th 2025The Phase II eNRGy trial showed durable antitumor activity with zenocutuzumab (Bizengri) in patients with NRG1 fusion–positive cancers, particularly non-small cell lung cancer and pancreatic cancer.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
SCOPE Summit 2025: Enhancing the Patient Experience Through Site Centricity
February 12th 2025In an interview with ACT senior editor Andy Studna at SCOPE Summit, Ashley Davidson, vice president, product lead - sponsor tech strategy, Advarra, highlights the need for more site-centric approaches in study startup.